vinblastine

Tumor tissue and serial plasma samples were collected from 15 patients with aUC treated with dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC). While the NOIR-SS-based assay proved sensitive and informative, limitations include the cost and time required for sequencing, potential temporal discordance between tissue and plasma sampling, and the absence of correction for clonal hematopoiesis of indeterminate potential. Overall, ctDNA profiling using this targeted panel and NOIR-SS suggested the feasibility of sensitive, non-invasive molecular monitoring in aUC, and may have future clinical applicability if validated prospectively in larger cohorts.

Systemic chemotherapy with vinblastine and prednisone led to marked improvement in nail, skin, pulmonary, and osseous lesions. These cases illustrate that nail changes may be the earliest manifestation of LCH and should prompt thorough systemic evaluation. Early recognition of nail involvement can facilitate timely diagnosis and risk-adapted treatment, potentially improving outcomes in affected patients.

High-throughput drug screening and molecular docking identified camptothecin (CPT) and vinblastine as showing strong therapeutic potential for high-risk patients. Experimental validation demonstrated that NDUFV2 was significantly overexpressed in GC tissues, and its knockdown markedly suppressed the proliferation, migration capacity, and intracellular ATP production in GC cells, confirming the critical role of NDUFV2 in GC progression. These findings establish NDUFV2 as a potential therapeutic target in GC.

P=N/A, N=118, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: May 2027 --> Jun 2026 | Trial primary completion date: May 2027 --> Jun 2026

P=N/A, N=118, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027

P2/3, N=131, Recruiting, National Cancer Institute (NCI) | N=249 --> 131

P2/3, N=370, Not yet recruiting, Polska Grupa Badawcza Chloniakow

P1/2, N=63, Terminated, Centre Oscar Lambret | Trial completion date: Jan 2027 --> Dec 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> May 2025; Analysis conducted on spring 2025, according to the provisional schedule: the results were sufficient to conclude about all endpoints, and the sponsor defined a new end of trial on 27 Dec 2025 (modification approved on CTIS on May 26, 2026).

Neoadjuvant ddMVAC plus durvalumab demonstrated encouraging pCR rates, favorable early survival outcomes, and manageable safety profile. Adding tremelimumab provides similar pCR but worse toxicity. These results support further study of ddMVAC plus durvalumab as a neoadjuvant chemoimmunotherapy strategy for localized MIBC, to be evaluated in comparative trials within an evolving perioperative treatment landscape.

P2, N=49, Completed, Northwestern University | Unknown status --> Completed

P2, N=78, Completed, Fox Chase Cancer Center | Active, not recruiting --> Completed | Trial completion date: Feb 2034 --> Dec 2025 | Trial primary completion date: Feb 2027 --> Nov 2025

The patient was treated with vinblastine and prednisolone, along with desmopressin and somatotropin replacement. Zoledronic acid was added for osseous disease...This case highlights an unusual presentation of adult LCH with distal lower-extremity and tarsal bone involvement, as well as hypothalamic-pituitary disease preceding osseous diagnosis by two years. It underscores the importance of considering LCH in adults with unexplained multifocal lytic bone lesions and endocrine dysfunction, and it demonstrates that durable disease control can be achieved with systemic therapy.